PREVENTIVE ANTIEPILEPTIC THERAPY IN PATIENTS WITH TUBEROUS SCLEROSIS
https://doi.org/10.17650/2073-8803-2017-12-2-34-39
Abstract
Background. Early detection of epileptiform activity on the electroencephalogram (EEG) and preventive antiepileptic therapy in patients with tuberous sclerosis (TS) help to avoid the development of severe forms of epilepsy as well as cognitive disorders associated with it.
Materials and methods. Seventeen patients with TS underwent preventive antiepileptic treatment in the Research and Clinical Institute for Pediatrics named after Y.E Vel’tishev. All patients were diagnosed with TS during their first months of life. The diagnosed was based on the detection of cardiac rhabdomyomas and hypopigmentation spots and then confirmed by a genetic test. Antiepileptic drugs (AED) (vigabatrin in 7 patients, valproic acid in 7 patients and levetiracetam in 2 patients) were administered after detection of epileptiform activity in the routine EEG (EEG was performed monthly).
Results. Preventive therapy with valproic acid and levetiracetam was found to be ineffective: 4 out of 7 patients on valproic acid and 1 out of 2 patients on levetiracetam developed epilepsy. All of them were later diagnosed with delayed psychological development and delayed speech development. Among 7 patients receiving vigabatrin, only 1 patient developed epilepsy, but did not have any developmental disorders later.
Conclusion. Despite vigabatrin is not registered in the Russian Federation, it should be used as an agent for preventive antiepileptic therapy in patients with TS. This approach ensures more favorable long-term results in terms of cognitive functions and psychological development, thus, providing a better quality of life.
About the Authors
A. V. Grigoryeva
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Epileptology and Psychoneurology, Research and Clinical Institute for Pediatrics named after Y.E Vel’tishev,
2 Taldomskaya Str., Moscow 125412
M. Yu. Dorofeeva
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Epileptology and Psychoneurology, Research and Clinical Institute for Pediatrics named after Y.E Vel’tishev,
2 Taldomskaya Str., Moscow 125412
Z. K. Gorchkhanova
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Epileptology and Psychoneurology, Research and Clinical Institute for Pediatrics named after Y.E Vel’tishev,
2 Taldomskaya Str., Moscow 125412
V. S. Perminov
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Epileptology and Psychoneurology, Research and Clinical Institute for Pediatrics named after Y.E Vel’tishev,
2 Taldomskaya Str., Moscow 125412
E. D. Belousova
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Epileptology and Psychoneurology, Research and Clinical Institute for Pediatrics named after Y.E Vel’tishev,
2 Taldomskaya Str., Moscow 125412
References
1. Белоусова Е.Д. Дорофеева М.Ю., Пивоварова А.М., Катышева О.В. Диагностика туберозного склероза. Журнал неврологии и психиатрии им. С.С. Корсакова 2015;115(5):46–51. [Belousiva E.D. Dorofeeva M.Yu., Pivovarova A.M., Katysheva O.V. Diagnosis of tuberous sclerosis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2015;115(5):46–51. (In Russ.)].
2. Cusmai R., Moavero R., Bombardieri R. et al. Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis. Epilepsy Behav 2011;22(4):735–9.
3. Curatolo P., Seri S. Seizures. In: Tuberous sclerosis complex. From basic science to clinical phenotypes. Ed. by P. Curatolo. London: Mac Keith Press, 2003. Pp. 47–76.
4. Crino P.B., Nathanson K.L., Henske E.P. The tuberous sclerosis complex. Review article. N Engl J Med 2006;355(13):1345–55. DOI: 10.1056/NEJMra055323.
5. Curatolo P., Bombardieri R., Verdecchia М., Cerminara C. Epileptic manifestations in tuberous sclerosis. In: Neurocutaneous syndromes in children. Eds. by P. Curatolo, D. Riva. Montrouge: John Libbey Eurotext, 2006. Pp. 91–100.
6. Curatolo P., Verdecchia М., Bombardieri R. Vigabatrin for tuberous sclerosis complex. Brain Dev 2001;23(7):649–53. PMID: 11701271.
7. Calcagnotto M.E., Paredes M.F. et al. Dysfunction of synaptic inhibition in epilepsy associated with focal cortical dysplasia. J Neurosci 2005;25(42):9649–57. DOI: 10.1523/JNEUROSCI.2687-05.2005
8. Camposano S.E., Major P. et al. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. Epilepsia 2008;49(7):1186–91. DOI: 10.1111/j.1528-1167.2008.01589.x.
9. Destuynder R., Menget A., Fromentin C. et al. Bourneville tuberous sclerosis manifested by prenatal finding of intracardiac tumors. Pediatrie 1992;47(4):279–84. PMID: 1329012.
10. Hancock E., Osborne J.P., Milner P. The treatment of West syndrome: a Cochrane review of the literature to December 2000. Brain Dev 2001;23(7):624–34. PMID: 11701267.
11. Hunt A. Psychiatric and psychological aspects. In: Tuberous sclerosis. Eds. by M. Gomes, J. Sampson, V. Whittemore. New York; Oxford: Oxford University Press, 1999. Pp. 47–62.
12. Jambaque I., Chiron С., Dumas C. et al. Mental and behavioural outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. Epilepsy Res 2000;38(2–3):151–60. PMID: 10642043.
13. Jóźwiak S., Kotulska K., DomańskaPakieła D. et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol 2011;15(5):424–31. DOI: 10.1016/j.ejpn.2011.03.010.
14. Karvelas G., Lortie A. et al. A retrospective study on aetiology based outcome of infantile spasms. Seizure 2009;18(3):197–201. DOI: 10.1016/j.seizure.2008.09.006.
15. Krueger D.A., Northrup H. Presented at: American Epilepsy Society Annual Meeting, Nov 30–Dec 4, 2012. San Diego, CA.
16. Napolioni V., Moavero R., Curatolo P. Recent advances in neurobiology of tuberous sclerosis complex. Brain Dev 2009;31(2):104–13. DOI: 10.1016/j.braindev.2008.09.013.
17. Osborne J. P., Fryer A., Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci 1991;615:125–8. PMID: 2039137.
18. Osborne J.P., O’Callaghan F.J.K. The management of tuberous sclerosis. Curr Paediatr 2003;13:365–70.
19. Parisi H., Bombardieri R., Curatolo P. Current role of vigabatrin in infantile spasms. Eur J Paediatr Neurol 2007;11(6):331–6. DOI: 10.1016/j.ejpn.2007.03.010.
20. Roach E.S., Di Mario F.J., Kandt R.S., Northrup H. Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. J Child Neur 1999;14(6):401–7. DOI: 10.1177/088307389901400610.
21. Roach E.S., Sparagana S.P. Diagnosis of tuberous sclerosis complex. J Child Neurol 2004;19(9):643–9. DOI: 10.1177/08830738040190090301.
22. Riikonen R.S. Favourable prognostic factors with infantile spasms. Eur J Paediatr Neurol 2010;14(1):13–8. DOI: 10.1016/j.ejpn.2009.03.004.
23. Curatolo P. Tuberous sclerosis. In: Infantile spasms and West syndrome. Eds. by O. Dulac, H.T. Chugani, B. Dalla Bernandina. London: W.B. Saunders Company Ltd., 1994. Pp. 192–202.
24. Tong X., O’Connell M.T. et al. Vigabatrin and GABA concentration interrelatioship in rat extracellular fluid (YАВ) from frontal cortex and hippocampus. Epilepsia 2000;41(7):95.
25. Thiele E.A., Weiner H.I. Epilepsy in TSC. In: Tuberous sclerosis complex. Genes, clinical features and therapeutics. Eds. by D.J. Kwiatkovski, V.H. Whittemore, E.A. Thiele. Weinheim: Wiley-Blackwell, 2010. Pp. 187–210.
26. Yancock E., Osborne J.P., Milner P. The treatment of West syndrome: a Cochrane rewiew of the literature to December 2000. Brain Dev 2001;23(7):624–34. PMID: 11701267.
27. Zhang B., McDaniel S.S., Rensing N.R., Wong M. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. PLoS One 2013;8(2):e57445. DOI: 10.1371/journal.pone.0057445.
Review
For citations:
Grigoryeva A.V., Dorofeeva M.Yu., Gorchkhanova Z.K., Perminov V.S., Belousova E.D. PREVENTIVE ANTIEPILEPTIC THERAPY IN PATIENTS WITH TUBEROUS SCLEROSIS. Russian Journal of Child Neurology. 2017;12(2):34-39. (In Russ.) https://doi.org/10.17650/2073-8803-2017-12-2-34-39
Views:
1193
Email this article 